ArticleFrontiers in oncology2025
Granulomatous lobular mastitis in pregnancy: report of 29 cases.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Targeted Therapy for Chronic Non-Bacterial Mastitis: New Insights into Pathophysiology and Therapeutic Strategies.International journal of women's health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulomatous lobular mastitis (GLM) is a rare inflammatory breast disease, and there are few reports of GLM in pregnancy (GLMIP). Therefore, this study retrospectively analyzed cases diagnosed with GLMIP from 2011 to 2023 and found that in patients with GLMIP there were varied demographic manifestations such as age, pregnancy weeks, and numbers of pregnancy and delivery, and several associated complications including erythema nodosum, arthritis and lower extremity edema. Among them, 82.8% of the patients received integrated traditional Chinese medicine (TCM) and western medicine treatment, and 17.2% of the patients received TCM treatment alone, but the application rate of TCM treatment was 100%. The results showed that both groups significantly improved the effective rate (91.7% and 60.0%, respectively), improved breast appearance (4.1% and 20.0%, respectively), reduced the rate of progression or recurrence rate (8.3% and 60.0%, respectively), and shortened the time for complete remission (13.793 months vs 12.625 months, respectively). To date this study is the one with the largest sample size of GLMIP, but also the one with the largest sample size in which the combination of TCM treatment and non-surgical treatment was applied. The complications include erythema nodosum, arthritis and lower extremity edema. Therefore, the application of TCM in the treatment of GLMIP is worth promoting vigorously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.